Jeena Sikho Lifecare Past Earnings Performance
Past criteria checks 5/6
Jeena Sikho Lifecare has been growing earnings at an average annual rate of 43.1%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 56.6% per year. Jeena Sikho Lifecare's return on equity is 35.1%, and it has net margins of 19.8%.
Key information
43.1%
Earnings growth rate
37.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 56.6% |
| Return on equity | 35.1% |
| Net Margin | 19.8% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Should You Be Adding Jeena Sikho Lifecare (NSE:JSLL) To Your Watchlist Today?
Apr 03
With Jeena Sikho Lifecare Limited (NSE:JSLL) It Looks Like You'll Get What You Pay For
Feb 08Here's Why We Think Jeena Sikho Lifecare (NSE:JSLL) Is Well Worth Watching
Nov 01With EPS Growth And More, Jeena Sikho Lifecare (NSE:JSLL) Makes An Interesting Case
Jul 15Jeena Sikho Lifecare Limited's (NSE:JSLL) Shares Climb 41% But Its Business Is Yet to Catch Up
Nov 18Jeena Sikho Lifecare's (NSE:JSLL) Solid Profits Have Weak Fundamentals
Aug 02Calculating The Intrinsic Value Of Jeena Sikho Lifecare Limited (NSE:JSLL)
Jul 21Revenue & Expenses BreakdownBeta
How Jeena Sikho Lifecare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 2,752 | 545 | 903 | 0 |
| 30 Jun 23 | 2,400 | 442 | 850 | 0 |
| 31 Mar 23 | 2,048 | 338 | 797 | 0 |
| 31 Mar 22 | 1,466 | 112 | 706 | 0 |
| 31 Mar 21 | 1,358 | 102 | 650 | 0 |
| 31 Mar 20 | 944 | 57 | 216 | 0 |
| 31 Mar 19 | 1,058 | 60 | 144 | 0 |
Quality Earnings: JSLL has a high level of non-cash earnings.
Growing Profit Margin: JSLL's current net profit margins (19.8%) are higher than last year (12.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JSLL's earnings have grown significantly by 43.1% per year over the past 5 years.
Accelerating Growth: JSLL's earnings growth over the past year (141.9%) exceeds its 5-year average (43.1% per year).
Earnings vs Industry: JSLL earnings growth over the past year (141.9%) exceeded the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: JSLL's Return on Equity (35.1%) is considered high.